Parkinson's disease is a neurodegenerative pathology which affects the dopaminergic neurons in the mesencephalon, leading to a progressive and relentless motor disability and to non-motor symptoms of different severity. The aim of this review is to summarize the features of drugs currently used in the pharmacotherapy of Parkinson's disease, with a look at their beneficial effects and limitations. Drugs acting on dopamine transmission, as L-DOPA, direct dopaminergic agonists, inhibitors for either the MAO or COMT enzymes and drugs acting on neurotransmitters other than dopamine (e.g. acetylcholine, glutamate) will be covered. Investigational drugs currently under examination for their therapeutic potential in Parkinson's disease and recent patents which may be relevant to the field will be also discussed

Pharmacological therapy of Parkinson's disease: current options and new avenues

SIMOLA, NICOLA;PINNA, ANNALISA;FENU, SANDRO
2010-01-01

Abstract

Parkinson's disease is a neurodegenerative pathology which affects the dopaminergic neurons in the mesencephalon, leading to a progressive and relentless motor disability and to non-motor symptoms of different severity. The aim of this review is to summarize the features of drugs currently used in the pharmacotherapy of Parkinson's disease, with a look at their beneficial effects and limitations. Drugs acting on dopamine transmission, as L-DOPA, direct dopaminergic agonists, inhibitors for either the MAO or COMT enzymes and drugs acting on neurotransmitters other than dopamine (e.g. acetylcholine, glutamate) will be covered. Investigational drugs currently under examination for their therapeutic potential in Parkinson's disease and recent patents which may be relevant to the field will be also discussed
2010
L-DOPA, Dopamine direct agonists, MAO inhibitors, COMT inhibitors, Anticholinergics, Amantadine, Motor impairment, Parkinson's Disease, Neurodegenerative pathology, Dopaminergic neurons, Dopamine transmission, Neurotransmitters, Acetylcholine, Glutamate, Alzheimer's disease, SNc DAergic neurons, Olfactory dysfunction, Norepinephrine (NE), Serotonin, Acetylcholine (Ach)DA replacement therapy (DRT), Akinesia, Bradykinesia, Globus pallidus (GPe), Entopeduncular nucleus (EPN), Subthalamic nucleus (STN), Substantia nigra reticulata (SNr), Biosynthesis of dopamine, Bromocriptine, Lisuride, Pergolide, Apomorphine, Ropinirole, Pramipexole, Monoamine oxidases, Pardoprunox, Selegiline, Catechol-O-Methyl transferases, Cholinergic transmission, Memantine, Adenosine A2A receptor, Autonomic dysfunction, Cognitive impairment, Hallucinations, Psychosis, Neurobehavioral problems, Mood disorders
File in questo prodotto:
File Dimensione Formato  
Simola RPCNS 2010.pdf

Solo gestori archivio

Tipologia: versione editoriale
Dimensione 338.19 kB
Formato Adobe PDF
338.19 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11584/99906
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 9
  • ???jsp.display-item.citation.isi??? ND
social impact